Status:
COMPLETED
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
Clinical Practice Research Datalink
Conditions:
Infections, Papillomavirus
Eligibility:
FEMALE
15-25 years
Brief Summary
This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e. women with last menstrual ...
Detailed Description
Convenience sampling will be used in this study. It is planned to include all eligible pregnant women (included in CPRD GOLD and who fulfil to the inclusion/exclusion criteria) in each of the two coho...
Eligibility Criteria
Inclusion
- For the exposed cohort:
- All subjects must satisfy all of the following criteria at entry into the exposed cohort:
- Full date of first day of LMP available in the database or calculated from Estimated date of delivery (EDD).
- Female, aged between, and including, 15 and 25 years of age at LMP.
- Recorded in the CPRD GOLD for at least 12 months at LMP.
- First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th 2011.
- At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.
- Full date of Cervarix vaccination(s) available.
- First day of LMP available in the database or calculated from EDD between 30 days before and 90 days after any dose of Cervarix.
- Subject defined as acceptable in CPRD GOLD.
- For the non-exposed cohort:
- All subjects must satisfy all of the following criteria at entry into the non-exposed cohort:
- Full date of first day of LMP available in the database or calculated from EDD.
- Female, aged between, and including, 15 and 25 years of age at LMP.
- Recorded in the CPRD GOLD since at least 12 months at LMP.
- First day of LMP available in the database or calculated from EDD between September 1st 2008 and June 30th 2011.
- At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.
- Full date of Cervarix vaccination(s) available.
- First day of LMP available in the database or calculated from EDD between 120 days and 18 months after the last dose of Cervarix.
- Subject defined as acceptable in CPRD GOLD.
Exclusion
- For the exposed cohort:
- • Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.
- For the non-exposed cohort:
- Female with the first day LMP between 30 days before and 90 days after at least one dose of unspecified Human Papillomavirus vaccine and/or Gardasil.
- Female included for a previous pregnancy in the exposed cohort.
Key Trial Info
Start Date :
November 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
1046 Patients enrolled
Trial Details
Trial ID
NCT01905462
Start Date
November 1 2012
End Date
August 1 2013
Last Update
September 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
London, United Kingdom, SW1W 9SZ